ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 131,41
0,69%
Dow Jones
39 056,39
0,44%
DAX
18 498,38
0,32%
Brent Oil
83,515
0,78%
Bitcoin
61 481,69
-1,37%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Omega Therapeutics Inc (OMGA)

  7. Omega Therapeutics Inc (OMGA) Actualités

OMGA Omega Therapeutics Inc

2,145
-0,01 (-0,46%)
Après les heures de négociation
Dernière mise à jour : 22:52:46
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Omega Therapeutics Inc OMGA NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,01 -0,46% 2,145 22:52:46
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,15 1,96 2,16 2,145 2,155
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
08/5/202413:00GLOBEOmega Therapeutics Presents New Preclinical Data at ASGCT..
06/5/202413:06EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/5/202413:04EDGAR2Form 8-K - Current report
06/5/202413:00GLOBEOmega Therapeutics Reports First Quarter 2024 Financial..
23/4/202413:00GLOBEOmega Therapeutics to Present New Preclinical Data on..
09/4/202413:00GLOBEOmega Therapeutics Presents New Preclinical Data at AACR..
28/3/202414:15GLOBEOmega Therapeutics Reports Fourth Quarter and Full Year 2023..
06/3/202413:00GLOBEOmega Therapeutics Announces Two Poster Presentations at the..
09/2/202423:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202423:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:00EDGAR2Form 8-K - Current report
02/1/202422:05GLOBEOmega Therapeutics to Present at the 42nd Annual J.P. Morgan..
11/12/202322:00EDGAR2Form 8-K - Current report
04/12/202322:00GLOBEOmega Therapeutics to Participate in the H.C. Wainwright 4th..
28/11/202301:01PRNUSFlagship Pioneering Marks Official Opening of UK Hub with..
21/11/202312:00PRNUSFlagship Pioneering Unveils Quotient Therapeutics to Create..
20/11/202322:00GLOBEOmega Therapeutics to Participate in the Piper Sandler 35th..
13/11/202313:00GLOBEOmega Therapeutics Showcases Bidirectional and Multiplexed..
09/11/202313:03EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202313:03EDGAR2Form 8-K - Current report
09/11/202313:00GLOBEOmega Therapeutics Reports Third Quarter 2023 Financial..
07/11/202322:00GLOBEOmega Therapeutics to Participate in The Jefferies London..
31/10/202312:00GLOBEOmega Therapeutics Presents New Preclinical Data..
16/10/202313:00GLOBEOmega Therapeutics Presents New Preclinical Data Supporting..
11/10/202322:00GLOBEOmega Therapeutics Announces Two Poster Presentations on..
04/10/202322:00GLOBEOmega Therapeutics to Present New Preclinical Data on..
26/9/202323:29EDGAR2Form 8-K - Current report
26/9/202313:00GLOBEOmega Therapeutics Announces Promising Preliminary Clinical..
25/9/202322:00GLOBEOmega Therapeutics to Host Conference Call to Discuss..
22/9/202323:10EDGAR2Form 8-K - Current report
21/9/202322:00GLOBEOmega Therapeutics to Participate in Two Upcoming Investor..
11/9/202312:30PRNUSFlagship Pioneering Announces Appointment of Amanda Kay as..
29/8/202322:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/8/202322:30EDGAR2Form 3 - Initial statement of beneficial ownership of..
29/8/202313:03EDGAR2Form 8-K - Current report
29/8/202313:00GLOBEOmega Therapeutics Announces Updates to its Board of..
03/8/202323:13EDGAR2Form 8-K - Current report
03/8/202323:11EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
03/8/202322:01EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202322:00GLOBEOmega Therapeutics Reports Second Quarter 2023 Financial..
13/7/202322:00EDGAR2Form 8-K - Current report
12/7/202322:01EDGAR2Form 8-K - Current report
12/7/202313:00GLOBEOmega Therapeutics Appoints Chris Schade to its Board of..
01/6/202313:00GLOBEOmega Therapeutics to Participate in Two Upcoming Investor..
31/5/202314:30GLOBEAshvattha Therapeutics Expands Leadership Team with..
31/5/202313:00GLOBEOmega Therapeutics Presents New Preclinical Data..
16/5/202312:00PRNUSFlagship Pioneering Launches Metaphore Biotechnologies to..

Dernières Valeurs Consultées

NASDAQ
OMGA
Omega Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés